Dear Mr. Tibbs:
Please contact Dr. Judy A. Mikovits, the senior author of the article, at the Whittemore Peterson Institute, Reno, NV, through her e-mail at firstname.lastname@example.org. I would suggest her to look into the sensitivity of the XMRV (xenotropic murine leukemia virus-related virus) Assay among the laboratories who showed contradictory results for the detection of XMRV in CFS (Chronic Fatigue Syndrome) patients’ samples.
To confirm her discovery of the linkage between XMRV and CFS, she needs to demonstrate the decrease or eradication of XMRV in CFS patients before and after recovery from their CFS. HepC Herba’s herbal ingredients in their other combinations with other herbal ingredients had been shown to be active against Ecotropic Murine Leukemia Virus (EMLV). HepC Herba™ itself had also been shown to help those with chronic hepatitis C along with chronic fatigue to feel with more energy in two to three weeks of taking the product.
I suggest Dr. Mikovits or some scientist(s) to conduct a clinical research using HepC Herba™ to treat people with chronic fatigue syndrome (CFS) or chronic fatigue and immune dysfunction syndrome (CFIDS) for one to two months, and follow the assay of their peripheral blood mononuclear cells (PBMCs) for XMRV levels in conjunction with their recovery or partial recovery from CFS or CFIDS in two to four weeks (past experience). A parallel control study with healthy people should also be conducted for comparison.
This should settle the contradictory findings. This study may also help those with prostate cancer or prevent prostate cancer from XMRV, since it had been shown that XMRV could infect human cells and had previously been linked to prostate cancer.
I am planning to organize a research team to respond to the NIH’s Martin Delaney Collaboratory: Towards an HIV-1 Cure (U19). The Letter of Intent is due October 4, 2010. The Application is due November 4, 2010. The Funds available is $8.5M for fiscal year 2011 for 1-2 awards. Direct cost may range from $3 to 5 million per year for up to five years, i.e., $15 to 25 millions total for five years. More funds may be available when needed and can be justified.
The Collaborative Agreement requires two research projects and one administrative core. A research core is optional if needed. An education and research institute and a private sector are required in the collaborative agreement. One of them shall function as the primary applicant. Sage R&D can function as the primary applicant and collaborate with a university or a medical center with HIV/AIDS research program.
One research project I am considering is a basic research to study the immune response of HepC Herba™ or P-10 Herba™, and their combination. Another research project shall be a clinical research on using HepC Herba™, with or without P-10 Herba™, for treating HIV/AIDS patients with conventional antiretroviral combination therapy to see if the use of HepC Herba™ or in combination with P-10 Herba™ would: (1) alleviate the severe adverse side effects of the combination antiretroviral therapy, (2) protect the liver from the damaging effect of the antiretroviral drugs for long-term use, (3) sustain the undetectable viral load on the long-term basis to replace the much less tolerable, much less compliable, and much more costly antiretroviral combination therapy, and (4) prevent or treat HIV-AIDS related complications. This shall constitute a partial cure, if not the complete cure, to the HIV-1 problem.
I am considering to have you get involved in the core administration on the “Towards an HIV-1 Cure Collaborative Agreement with NIH” to assist me to pull the research team together and manage the supply of the HepC Herb™ and P-10 Herba™ to the researchers as needed. You are also authorized to contact Dr. Judy A. Mikovits and other researchers and venture capitalists or foundations on the potential collaboration and funding or venture for CFS or CFIDS and Prostate Cancer prevention and treatment. Please let me know. Thanks for your continuing support.
Shie-Ming Hwang, Ph.D.